Inactive Instrument

Alexion Pharmaceuticals, Inc. Stock Xetra

AXP

US0153511094

Latest news: Alexion Pharmaceuticals, Inc.

13/05	Alexion Reports Positive CALYPSO Phase III Trial Results For Eneboparatide In Adults With Hypoparathyroidism	CI
05/12	Neurimmune Expands Collaboration with Alexion to Develop and Commercialize Fibril Depleter NI009 for AL Amyloidosis	CI
20/11	Alexion, AstraZeneca Rare Disease's Koselugo (selumetinib) Approves in the US	CI
12/11/24	Alexion, AstraZeneca Rare Disease and Merck Announces Positive Topline Results from the Phase 3 Komet Trial	CI
25/10/24	Monopar Therapeutics Inc. acquired worldwide license to ALXN-18 from Alexion Pharmaceuticals, Inc. for approximately $110 million.	CI
24/10/24	Monopar Therapeutics Inc Announces Agreement with Alexion, AstraZeneca Rare Disease for Late-Stage Wilson Disease Drug Candidate	CI
01/04/24	Alexion Pharmaceuticals, Inc.'s VOYDEYA Receives Approval in US Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH	CI
11/12/23	Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS	CI
19/09/23	Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc..	CI
08/09/23	Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases	CI
28/07/23	Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion.	CI
30/03/23	JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease	CI
15/11/22	Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	CI

More news

Analysts' recommendations: Alexion Pharmaceuticals, Inc.

06/05/21	Alexion Pharmaceuticals : Oppenheimer Upgrades Alexion Pharmaceuticals to Outperform From Perform, $205 Price Target	MT
04/05/21	Alexion Pharmaceuticals : SVB Leerink Adjusts Alexion Pharmaceuticals PT to $173 From $156, Maintains Market Perform Rating	MT
23/03/21	Alexion Pharmaceuticals : SVB Leerink Downgrades Alexion Pharmaceuticals to Market Perform From Outperform, Adjusts Price Target to $156 From $196	MT
06/02/21	Alexion Pharmaceuticals : SVB Leerink Adjusts Price Target on Alexion Pharmaceuticals to $196 From $200, Maintains Outperform Rating	MT
09/01/21	Alexion Pharmaceuticals : Raymond James Downgrades Alexion Pharmaceuticals to Market Perform from Outperform	MT

More recommendations

Press Releases: Alexion Pharmaceuticals, Inc.

17/05/23	AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023	AQ
08/05/23	Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas	AQ
02/12/22	AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022	AQ
18/11/22	Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics	AQ
11/11/22	AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients in China	AQ

More press releases

News in other languages: Alexion Pharmaceuticals, Inc.

21/05/24	Astrazeneca vise une hausse de 75% de son chiffre d'affaires
05/06/23	Astrazeneca continue à muscler son portefeuille de médicaments
10/02/23	AstraZeneca: embellie en 2022 mais déclin attendu des médicaments anti-Covid
09/02/23	AstraZeneca: embellie des résultats 2022
29/04/22	Astrazeneca: bénéfice lesté de charges exceptionnelles

More news

Managers and Directors: Alexion Pharmaceuticals, Inc.

Manager	Title	Age	Since
Marc Dunoyer CEO	Chief Executive Officer	73	-
Sean Christie DFI	Director of Finance/CFO	53	01/08/2021
Doyle Shane COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Ruud Dobber BRD	Director/Board Member	-	-

More insiders

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company's marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.

Employees

3,837

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALEXION PHARMACEUTICALS, INC.	+0.72%	-2.74%	-	-	40.34B
ELI LILLY AND COMPANY	+2.68%	+2.56%	+59.32%	+114.68%	1,053B
JOHNSON & JOHNSON	+0.56%	+0.17%	+53.19%	+68.65%	652B
ABBVIE INC.	+0.02%	+0.42%	+20.51%	+73.58%	468B
ROCHE HOLDING AG	-0.10%	+1.96%	+42.67%	+45.78%	351B
NOVARTIS AG	+0.67%	+4.01%	+22.16%	+29.43%	273B
ASTRAZENECA PLC	+1.31%	+0.78%	+14.99%	+12.54%	254B
AMGEN INC.	-0.01%	+6.91%	+45.42%	+51.68%	220B
GILEAD SCIENCES, INC.	-1.11%	-0.80%	+31.69%	+99.56%	186B
NOVO NORDISK A/S	+0.08%	-10.14%	-29.94%	-60.30%	170B
Average	+0.21%	+0.30%	+28.89%	+48.40%	403.04B
Weighted average by Cap.	+0.18%	+1.00%	+39.25%	+68.07%

Alexion Pharmaceuticals, Inc. Stock Xetra

Stocks

AXP